Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Summary: Several recent studies have shown that a single intravenous subanesthetic dose of ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with treatment refractory mood disorders and reduces suicidal ideation. Those insights have fueled tremendous excitement in the efforts to elucidate the mechanism underlying ketamine's antidepressant properties in animal models of depression, as well as in humans through the use of brain imaging as well as peripheral blood measurements. For example, there is emerging evidence that ketamine's antidepressant properties rely on increasing AMPA signaling and rapidly inducing synaptogenesis. While pilot clinical studies are promising, a number of critical questions still remain unanswered. They relate to the safe and effective use of ketamine in patients with mood disorders regarding the optimal dose range, modality and method of administration for acute and long‐term maintenance of effect, and the biomarkers associated with response/nonresponse. In this review article, we first summarize the clinical evidence about the use of ketamine in mood disorders, as well as preclinical and humans studies which investigated the mechanisms of action of ketamine, and predictors of antidepressant response in clinical populations. We then provide a critical overview of the knowledge gaps about the use of ketamine in depression and suggest some future research directions for the investigation of ketamine as a promising tool to develop novel more effective and fast acting antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“[33], who showed activation of the mTOR complex and key components of translation initiation, p70 ribosomal S6 kinase (p70S6K) and eIF4E-binding after administration of subanesthetic ketamine (10 mg/kg).”
BackgroundSleep function and synaptic homeostasis
Tononi, G., & Cirelli, C. (2006) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.05.002 · Cited by 2,151 · cited 1×
“According to the synaptic homeostasis hypothesis, SWA might reflect brain plasticity [60]: this might suggest that responders to ketamine are characterized by lower brain plasticity, which might then be increased by ketamine [42].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“Increase in BDNF protein levels was found in the hippocampus but not in nucleus accumbens, possibly suggesting a region specific effect [31].”
BackgroundInfluentialMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 3×
“[24] showed increased extracellular glutamate in the prefrontal cortex in awake animals, as well as increased dopamine release; increase in glutamate release was observed with low doses of ketamine (i.”
BackgroundResultInfluentialSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“, 2012 for a comprehensive review on the topic [22]).”
BackgroundHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“prefrontal cortex [29].”
Sheline, Y. I., Price, J. L., Yan, Z., & Mintun, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000446107 · Cited by 1,196
Raichle, M. E. (2010) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2010.01.008 · Cited by 1,111 · cited 1×
“As the DMN is associated with self-referential processes and ruminations [52] and shows increased fc in subjects with depression, a decrease in fc after ketamine might reflect restoration of a normative pattern which might be associated with antidepressant response.”
Background
Cited by
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Self-citationOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
“…would suggest that interventions which directly (e.g., ketamine and riluzole) or indirectly (e.g., scopolamine) modulate glutamate function may mitigate depressive symptoms in individuals with MDD (Khajavi et al., 2012; Salvadore and Singh, 2013; Carlson et al., 2013; Kavalali and Monteggia, 2012).”
BackgroundKetamine use in current clinical practice
Gao, M., Rejaei, D., & Liu, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.5 · Cited by 286
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
“However, even the low-dose ketamine used in the depression studies causes psychotomimetic effects in some patients, with the potential for abuse (19).”
BackgroundKetamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120
“Its use for medical indications is attributable to its safety and wide therapeutic range [3].”
BackgroundInfluentialChen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.033 · Cited by 86
Visceral Inflammation and Immune Activation Stress the Brain
Holzer, P., Farzi, A., Hassan, A. M., Zenz, G., Jačan, A., & Reichmann, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01613 · Cited by 84
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Metadata
- Authors
- Salvadore, G., & Singh, J. B.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2013-04-12
- Volume
- 19
- Issue
- 6
- Pages
- 428-436
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2120065705
- Cited by
- 81
- References
- 35
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.